There are diagnostic methods based on biomarker detection; cerebrospinal fluid (CSF) biomarkers Aβ1-42, T-tau, and P-tau are well-validated, and are being increasingly used in clinical practice as tools for the affirmative diagnosis of AD [41]. This evidence concerns the gene MAPT and Alzheimer disease.